KRCA-0008 is primarily utilized in the field of medical research, particularly in the study of cancer therapies. It functions as a potent inhibitor targeting specific pathways involved in tumor growth and proliferation. Researchers employ this compound to investigate its efficacy in halting the progression of various cancer types, including but not limited to breast, lung, and colon cancers. Its application extends to preclinical studies where it is tested in animal models to assess its potential as a therapeutic agent. Additionally, KRCA-0008 is used in biochemical assays to better understand the molecular mechanisms underlying cancer cell survival and resistance to treatment. This compound is also explored in combination therapies, where it is paired with other anticancer drugs to enhance overall treatment outcomes and reduce the likelihood of drug resistance.